Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Guangdong General Hospital · Guangdong Academy of Medical Sciences · +31 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
527
total citations
- FWCI
- 40.61
- Percentile
- 100%
- References
- 32
Citations per year
Authors
54- WZWen‐Zhao Zhong
Guangdong General Hospital, Guangdong Academy of Medical Sciences
- QWQun Wang
The First Affiliated Hospital, Sun Yat-sen University, Zhongshan Hospital, Sun Yat-sen University, Fudan University
- WMWeimin Mao
Zhejiang Cancer Hospital
- LXLin Xu
First Hospital of China Medical University, Fudan University, China Medical University, Third Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Affiliated Hospital, Sun Yat-sen University, Zhongshan Hospital, Sun Yat-sen University
- LWLin Wu
Hunan Cancer Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Vinorelbine
- Gefitinib
- Internal medicine
- Clinical endpoint
- Oncology
- Population
- non-small cell lung cancer (NSCLC)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.